BNTX Dec 2024 70.000 call
- PA Media: Money
Covid-19 vaccine patent legal battle heading to Court of Appeal
Moderna, Pfizer and BioNTech are locked in dispute over the rights to vaccine technology patents.
- Reuters
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022, seeking to revoke two patents held by Moderna, which hit back days later alleging its own patents had been infringed.
- CNW Group
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages.
